We have located links that may give you full text access.
English Abstract
Journal Article
Review
[Role of Immunotherapy in Pediatric Oncology].
BACKGROUND: Currently, most children with cancer can be cured with standard therapy (surgery, chemotherapy, radiotherapy). The only limiting factor is its severe acute toxicity and late adverse events. In pediatric oncology, immunotherapy has been delayed but the initial clinical trials of immunotherapy show a good tolerance and promising results, especially in the setting of refractory or recurrent high-risk tumors. In this article, we will discuss a current situation in pediatric oncology, what immunotherapies are being tested in the clinical practice, from monoclonal antibodies, check- point inhibitors to tumor vaccines, T-lymphocytes with chimeric antigen receptors, cytokines and innate immunity.
CONCLUSION: Immunotherapy is a promising treatment modality for children and adolescents with recurrent high-risk cancer with potential to improve both survival and quality of life. The challenge of developing immunotherapies in pediatric oncology remains - age barriers for using new drugs and a limited number of pediatric clinical studies.
CONCLUSION: Immunotherapy is a promising treatment modality for children and adolescents with recurrent high-risk cancer with potential to improve both survival and quality of life. The challenge of developing immunotherapies in pediatric oncology remains - age barriers for using new drugs and a limited number of pediatric clinical studies.
Full text links
Related Resources
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app
All material on this website is protected by copyright, Copyright © 1994-2024 by WebMD LLC.
This website also contains material copyrighted by 3rd parties.
By using this service, you agree to our terms of use and privacy policy.
Your Privacy Choices
You can now claim free CME credits for this literature searchClaim now
Get seemless 1-tap access through your institution/university
For the best experience, use the Read mobile app